Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CRDF - Cardiff Oncology, Inc.

IEX Last Trade
4.25
0.050   1.176%

Share volume: 14,494
Last Updated: Fri 27 Dec 2024 06:30:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.40%

PREVIOUS CLOSE
CHG
CHG%
$4.20
0.05
1.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 8%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.69%
1 Month
59.35%
3 Months
42.03%
6 Months
67.52%
1 Year
152.90%
2 Year
208.66%
Key data
Stock price
$4.25
P/E Ratio 
0.00
DAY RANGE
$4.14 - $4.54
EPS 
$0.00
52 WEEK RANGE
$1.51 - $6.42
52 WEEK CHANGE
$170.34
MARKET CAP 
107.530 M
YIELD 
N/A
SHARES OUTSTANDING 
46.550 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,509,339
AVERAGE 30 VOLUME 
$4,331,495
Company detail
CEO: Mark Erlander
Region: US
Website: cardiffoncology.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.

Recent news